文献速递糖尿病

磺脲类药物的药理学差异与心血管不良事件及低血糖风险

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
PubMed 文献 · Diabetes Care · 2017-09-01

基于英国临床实践研究数据链的队列研究,纳入1998至2013年启动磺脲类单药治疗的2型糖尿病患者17,604例,比较胰腺非特异性长效磺脲类(格列本脲/格列美脲)与胰腺特异性短效磺脲类(格列齐特/格列吡嗪/甲苯磺丁脲)的心血管不良事件及严重低血糖风险。结果发现两组急性心肌梗死、缺血性卒中、心血管死亡及全因死亡风险无显著差异,但非特异性长效磺脲类的严重低血糖风险增加(HR 2.83)。

要点

  • 非特异性长效磺脲类与特异性短效磺脲类的心血管不良事件风险无显著差异。
  • 非特异性长效磺脲类严重低血糖风险为特异性短效磺脲类的2.83倍(HR 2.83;CI 1.64-4.88)。

核心结论

  • 格列本脲和格列美脲等非特异性长效磺脲类与格列齐特、格列吡嗪和甲苯磺丁脲等特异性短效磺脲类相比,心血管不良事件风险未增加,但严重低血糖风险增加。

研究设计与样本

  • 使用英国临床实践研究数据链(链接医院统计和英国国家统计办公室数据库)开展队列研究,纳入1998至2013年启动磺脲类单药治疗的2型糖尿病患者17,604例,平均随访1.2(标准差1.5)年。
  • 采用Cox比例风险模型估计校正风险比(HR)和95%置信区间(CI),比较胰腺非特异性长效磺脲类(格列本脲/格列美脲)与胰腺特异性短效磺脲类(格列齐特/格列吡嗪/甲苯磺丁脲)。

主要发现

  • 非特异性长效磺脲类(1,863例)与特异性短效磺脲类(15,741例)相比,急性心肌梗死风险无显著差异(HR 0.86;CI 0.55-1.34)。
  • 缺血性卒中风险无显著差异(HR 0.92;CI 0.59-1.45)。
  • 心血管死亡风险无显著差异(HR 1.01;CI 0.72-1.40)。
  • 全因死亡风险无显著差异(HR 0.81;CI 0.66-1.003)。
  • 严重低血糖风险增加(HR 2.83;CI 1.64-4.88)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sulfonylureas have been associated with an increased risk of cardiovascular adverse events and hypoglycemia, but it is unclear if these risks vary with different agents. We assessed whether the risks of acute myocardial infarction, ischemic stroke, cardiovascular death, all-cause mortality, and severe hypoglycemia differ between sulfonylureas grouped according to pancreas specificity and duration of action. RESEARCH DESIGN AND METHODS: Using the U.K. Clinical Practice Research Datalink, linked with the Hospital Episodes Statistics and the Office for National Statistics databases, we conducted a cohort study among patients with type 2 diabetes initiating monotherapy with sulfonylureas between 1998 and 2013. Adjusted hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models, comparing use of pancreas-nonspecific, long-acting sulfonylureas (glyburide/glimepiride) to pancreas-specific, short-acting sulfonylureas (gliclazide/glipizide/tolbutamide). RESULTS: The cohort included 17,604 sulfonylurea initiators (mean [SD] follow-up 1.2 [1.5] years). Compared with specific, short-acting sulfonylureas (15,741 initiators), nonspecific, long-acting sulfonylureas (1,863 initiators) were not associated with an increased risk of acute myocardial infarction (HR 0.86; CI 0.55-1.34), ischemic stroke (HR 0.92; CI 0.59-1.45), cardiovascular death (HR 1.01; CI 0.72-1.40), or all-cause mortality (HR 0.81; CI 0.66-1.003), but with an increased risk of severe hypoglycemia (HR 2.83; CI 1.64-4.88). CONCLUSIONS: The nonspecific, long-acting sulfonylureas glyburide and glimepiride do not have an increased risk of cardiovascular adverse events compared with the specific, short-acting sulfonylureas gliclazide, glipizide, and tolbutamide. However, nonspecific, long-acting sulfonylureas glyburide and glimepiride have an increased risk of severe hypoglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Douros A, Yin H, Yu OHY, et al. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. 2017. PMID: 28864502. doi:10.2337/dc17-0595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。